Browse > Article
http://dx.doi.org/10.5352/JLS.2015.25.1.113

Current Medical Therapies for Osteoporosis and Its Alternative Treatments Using Natural Products  

Oh, Seunghoon (Department of Physiology, College of Medicine, Dankook University)
Ahn, Soon-Cheol (Department of Microbiology and Immunology, Pusan National University School of Medicine)
Publication Information
Journal of Life Science / v.25, no.1, 2015 , pp. 113-120 More about this Journal
Abstract
Osteoporosis is a major bone disorder defined as having bone mineral density (BMD) of 2.5 standard deviations or more below the peak bone mass. Osteoporosis will increasingly be a major disorder that faces the aging mankind. It is the result of an imbalance in the bone remodeling system, where bone constantly undergoes a cycle of resorption by osteoclasts and formation by osteoblasts. Estrogen deficiency in women following menopause is identified as the predominant reason that causes disparity in this system. Current medical treatments for osteoporosis include hormone replacement therapy (HRT), biphosphonates, and teriparatide, but have various side effects that raise questions concerning their medical safety and practicality. Alternative treatments involving natural product sources are under study to find a safer therapy. Many natural sources including lactoferrin and isoflavones and numerous traditional herbal medicines exhibit anti-resorptive or anabolic effects on bone and thus show promises to provide therapeutic agents in treating osteoporosis. Unfortunately, the majority of natural product treatments are still in its preliminary stages to prove their efficacy even though the development pace of treatment for osteoporosis is astounding in the past few decades. Further progress in pre-clinical studies and the subsequent clinical studies will someday lead to a breakthrough that takes us another step forward in science.
Keywords
Alternative therapy; natural product; osteoblast; osteoclast; osteoporosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 World Health Organization (WHO). 1994. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843, 1-129.
2 Wuttke, W., Seidlova-Wuttke, D. and Gorkow, C. 2003. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 44, S67-S77.   DOI
3 Yang, Q., Populo, S. M., Zhang, J., Yang, G. and Kodama,H. 2002. Effect of Angelica sinensis on the proliferation of human bone cells. Clinica Chimica Acta 324, 89-97.   DOI
4 Yin, J., Tezuka, Y., Subehan, Shi, L., Nobukawa, M., Nobukawa, T. and Kadota, S. 2006. In vivo anti-osteoporotic activity of isotaxiresinol, a lignan from wood of Taxus yunnanensis. Phytomedicine 13, 37-42.   DOI
5 Zhang, Y., Leung, P. C., Che, C. T., Chow, H. K., Wu, C.F. and Wong, M. S. 2008. Improvement of bone properties and enhancement of mineralization by ethanol extract of fructus Ligustri lucidi. Br. J. Nutr. 99, 494-502.
6 Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289, 1504-1508.   DOI   ScienceOn
7 Song, K. B., Atkinson, C., Frankenfeld, C. L., Jokela, T.,Wahala, K., Thomas, W. K. and Lampe, J. W. 2006. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J. Nutr. 136, 1347-1351.   DOI
8 Song, L., Zhao, J., Zhang, X., Li, H. and Zhou, Y. 2013. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur. J. Pharmacol. 714, 15-22.   DOI
9 Subbiah, V., Madsen, V. S., Raymond, A. K., Benjamin, R.S. and Ludwig, J. A. 2010. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 21, 1041- 1045.   DOI
10 Wang, P. P., Zhu, X. F., Yang, L., Liang, H., Feng, S. W. and Zhang, R. H. 2012. Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/β-catenin pathways. J. Asian Nat. Prod. Res. 14, 897-905.   DOI
11 Wetli, H. A., Brenneisen, R., Tschudi, I., Langos, M., Bigler,P., Sprang, T., Schürch, S. and Mühlauer, R. C. 2005. A gamma-glutamyl peptide isolated from onion (Allium cepa L.)by bioassay guided fractionation inhibits resorption activity of osteoclasts. J. Agric. Food Chem. 53, 3408-3414   DOI
12 Whelan, A. M., Jurgen, T. M., Bowles, S. K. and Doyle, H. 2009. Efficacy of natural health products in treating osteoporosis: what is the quality of internet patient advice?. Ann. Pharmacother. 43, 899-907.   DOI
13 Woo, S., Hellstein, J. and Kalmar, J. 2006. Narrative review: biphosphates and osteonecrosis of the jaws. Ann. Intern. Med. 144, 753-761.   DOI
14 Saag, K. G., Shane, E., Boonen, S., Marin, F., Dongley, D.W., Taylor, K. A., Dalsky, G. P. and Marcus, R. 2007. Teriparatideor alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039   DOI
15 Raisz, L. G. 2005. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325.   DOI
16 Rodan, G. A. and Martin, T. J. 2000. Therapeutic approaches to bone diseases. Science 289, 1508-1514.   DOI
17 Rodan, G. A., Raisz, L. G. and Bilezikian, J. P. 2002. Pathophysiology of osteoporosis. Principles of Bone Biology San Diego: Academic Press.
18 Sethi, G. and Aggarwal, B. B. 2007. Mending the bones with natural products. Chem. Biol. 14, 738-740.   DOI
19 Santiago-Mora, R., Casado-Díaz, A., De Castro, M. D. and Quesada-Gómez, J. M. 2011. Oleuropein enhances osteo-blastogenesis and inhibits adipogenesis: the effect on differentiation in stem cells derived from bone marrow. Osteoporos Int. 22, 675-684.   DOI   ScienceOn
20 Setchell, K. D. R., Brown, N. M. and Lydeking-Olsen, E. 2002. The clinical importance of the metabolite equol - aclue to the effectiveness of soy and its isoflavones. J. Nutr. 132, 3577-3684.   DOI
21 Shishodia, S., Sethi, G. and Aggarwal, B. B. 2005. Curcumin:getting back to the roots. Ann N Y Acad Sci 1056, 206-217.   DOI
22 Somjen, D. and Yoles, I. 2003. DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J. Steroid Biochem.Mol. Biol. 86, 93-98.   DOI
23 Muhlbauer, R. C., Lozano, A., Palacio, S., Reinli, A. and Felix, R. 2003. Common herbs, essential oils, and monoterpenes potently modulate bone metabolism. Bone 32, 372-380.   DOI
24 Li, J. X., Liu, J., He, C. C., Yu, Z. Y., Du, Y., Kadota, S. and Seto, H. 2007. Triterpenoids from Cimicifugae rhizoma, a novel class of inhibitors on bone resorption and ovariectomy-induced bone loss. Maturitas 58, 59-69.   DOI   ScienceOn
25 Li, N., Jiang, Y., Wooley, P. H., Xu, Z. and Yang, S. Y. 2013. Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. J. Orthop. Sci. 18, 478-485.   DOI
26 Messina, M. 2010. A brief historical overview of the past two decades of soy and isoflavone research. J. Nutr. 140, 1350-1354.   DOI
27 Pan, W., Quarles, L. D., Song, L. H., Yu, Y. H., Jiao, C.,Tang, H. B., Jiang, C. H., Deng, H. W., Li, Y. J., Zhou, H.H. and Xiao, Z. S. 2005. Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J. Cell Biochem. 94, 307-316.   DOI
28 Nakagawa, H., Wachi, M., Woo, J. T., Kato, M., Kasai, S., Takahashi, F., Lee, I. S. and Nagai, K. 2002. Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem. Biophys. Res. Commun. 292, 94-101   DOI
29 National Osteoporosis Foundation. 2010. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC. National Osteoporosis Foundation.
30 Ott, S. M. 2005. Long-term safety of biphosphonates. J. Clin. Endocrinol. Metab. 90, 1897-1899.   DOI
31 Khosla, S. 2001. Minireview: The OPG/RANKL/RANK system. Endocrinology 142, 5050-5055.   DOI
32 Putnam, S. E., Scutt, A. M., Bicknell, K., Priestley, C. M.and Williamson, E. M. 2007. Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother. Res. 21, 99-112.   DOI
33 Hsu, C. H. and Cheng, A. L. 2007. Clinical studies with curcumin. Adv. Exp. Med. Biol. 595, 471-480.   DOI
34 Jeong, J. C., Lee, J. W., Yoon, C. H., Lee, Y. C., Chung, K. H., Kim, M. G. and Kim, C. H. 2005. Stimulative effects of Drynariae Rhizoma extracts on the proliferation and differentiation of osteoblastic MC3T3-E1 cells. J. Ethnopharmacol. 96, 489-495.37.   DOI
35 Li, F., Sun, X., Ma, J., Ma, X., Zhao, B., Zhang, Y., Tian, P.,Li, Y. and Han, Z. 2014. Naringin prevents ovariectomy-induce dosteoporosis and promotes osteoclasts apoptosis through the mitochondria-mediated apoptosis pathway. Biochem. Biophys. Res. Commun. 452, 629-635.   DOI
36 Kim, K. W., Suh, S. J., Lee, T. K., Ha, K. T., Kim, J. K., Kim,K. H., Kim, D. I., Jeon, J. H., Moon, T. C. and Kim, C. H. 2008. Effect of safflower seeds supplementation on stimulation of the proliferation, differentiation and mineralization osteoblastic MC3T3-E1 cells. J. Ethnopharmacol. 115, 42-49.   DOI
37 Kohrt, W. M., Snead, D. B., Slatopolsky, E. and Birge, S. J. 1995. Additive effects of weight-bearing exercise and estrogenon bone mineral density in older women. J. BoneMiner. Res. 10, 1303-1311.
38 Lee, S. U., Park, S. J., Kwak, H. B., Oh, J., Min, Y. K. and Kim, S. H. 2008. Anabolic activity of ursolic acid in bone: stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. Pharmacol. Res. 58, 290-296.   DOI
39 Cornish, J., Callon, K. E., Naot, D., Palmano, K. P., Banovic,T., Bava, U., Watson, M., Lin, J., Tong, P. C., Chen, Q., Chan,V. A ., Haggarty, N. W., Grey, A. B. and Reid, I. R. 2004. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145, 4366-4374.   DOI
40 Li, F., Yang, Y., Zhu, P., Chen, W., Qi, D., Shi, X., Zhang, C., Yang, Z. and Li, P. 2012. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells. Fitoterapia 83, 1443-1450.   DOI
41 Cassidy, A., Albertazzi, P., Nielsen, I. L., Hall, W.,Williamson, G., Tetens, I., Atkins, S., Cross, H., Manios, Y.,Wolk, A., Steiner, C. and Branca, F. 2006. Critical review of health effects of soyabean phyto-oestrogens in post-men-opausal women. Proc. Nutr. Soc. 65, 76-92.   DOI
42 Fonseca, D. and Ward, W. E. 2004. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone 35, 489-497.   DOI
43 Chen, C. H., Ho, M. L., Chang, J. K., Hung, S. H. and Wang, G. J. 2005. Green tea catech in enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporos Int. 16, 2039-2045.   DOI
44 Cotter, A. and Cashman, K. D. 2003. Genistein appears to prevent early postmenopausal bone loss as effectively as hormone replacement therapy. Nutr. Rev. 61, 346-351.   DOI
45 Devareddy, L., Khalil, D. A., Korlagunta, K., Hooshmand,S., Bellmer, D. D. and Arjmandi, B. H. 2006. The effects of fructooligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats. Menopause 13,692-699.   DOI
46 Frankenfeld, C. L., Atkinson, C., Thomas, W. K., Gonzalez,A., Jokela, T., Wahala, K., Schwartz, S. M., Li, S. S. and Lampe, J. W. 2005. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart.Br. J. Nutr. 94, 873-876.   DOI
47 Hill, P. A. 1998. Bone Remodeling. Br. J. Orthod. 25, 101-107.   DOI
48 Bharti, A. C., Takada, Y. and Aggarwa, B. B. 2004. Curcumin (diferulolylmethane) inhibits receptor activator of NF-κ B ligand-induced NF-κ B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol. 172, 5940-5947.   DOI
49 Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F. and Cummings, S. R. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N. Engl. J. Med. 356, 1809-1822.   DOI
50 Branca, F. 2003. Dietary phyto-oestrogens and bone health.Proc. Nutr. Soc. 62, 877-887.   DOI
51 Brenneman, S. K., Barrett-Connor, E. S., Sajjan, L. E., Markson and Siris, E. S. 2006. Impact of recent fracture on health-related quality of life in postmenopausal women. J. Bone Miner. Res. 21, 809-816.   DOI
52 Brouns, F. and Vermeer, C. 2000. Functional food ingredients for reducing the risks of osteoporosis. Trends Food Sci. Technol. 11, 22-33.   DOI